Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.
Immunotherapies—meaning bispecifics and CAR T—are going to change the way we take care of our disease. We need to figure out how to make sure all patients will have access to these novel therapies, these novel immunotherapies, or these T cell–engaging therapies. We’re on the horizon of understanding what they mean clinically, and how they work in the context of the immune microenvironment.
Transcript edited for clarity.